Angiodynamics (ANGO): CFO sold ~$21K
Stephen A Trowbridge, CFO at Angiodynamics, sold ~$21K of Angiodynamics shares.
- ~$21K
- Approx. value · 1,720 sh @ $12.17
- 304K
- Holds after · shares reported
- Traded
- Oct 28, 2026
- Filed
- Oct 30, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Oct 2, 2026Company filing · Form 8-K · Material agreement, Executive changeChanged a top executive or board member, and signed an important agreement“On October 2, 2026, the Board of Directors of the Company (the “ Board ”) appointed Eric Honroth to serve as President and Chief Executive Officer of the Company, effective as of November 2, 2026 (the “ Effective Date ”) and concurrently with Mr. Clemmer’s retirement.”
- Oct 8, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
- Oct 28, 2026 · this disclosureInsiderCFO sold ~$21K of ANGO shares in the open market
What came next
- Oct 29, 2026InsiderCFO sold ~$290K of ANGO shares in the open market
- Oct 30, 2026FDAFDA device clearance: AngioVac F1885
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Angiodynamics
For Angiodynamics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ANGO page.
Other recent filings by Stephen A Trowbridge, EVP and CFO
The full history of Stephen A Trowbridge, EVP and CFO is on the profile page.
How this filing works
Explore the data
Other disclosures at Angiodynamics
- SEC Form 4Oct 30, 2026
- SEC Form 144Oct 29, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRMay 15, 2026
- SEC Form 13F-HRMay 13, 2026
Everything OQRO holds on this company is on its ANGO page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
